Investegate announcements from Ultimovacs ASA, Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingLONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage bi.
Upcoming Panel Discussion, Hosted by Xtalks on Precision Oncology: An Era that Calls for a New Model for Conducting Clinical Trials?
Share Article
During this discussion, the featured speakers will examine lessons learnt from the clinical development of targeted therapies such as immunotherapeutic agents, and current methodological challenges for new drug development in the precision oncology era. They will provide insights into a novel approach to conduct clinical research in the precision oncology era.
Clinical trials have evolved from drug- to target-oriented trials, and this shift has raised several challenges. TORONTO, Ontario (PRWEB) June 04, 2021 Genomic sequencing techniques and bioinformatics have led us to a better understanding of cancer biology, resulting in a shift from empirical strategies to molecular (precision oncology) and immunological therapeutic approaches in clinical oncology. Consequently,
/PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision.
UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster presentation